Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
MedDay
Biotech
MedDay's multiple sclerosis drug a bust in phase 3
MedDay's multiple sclerosis drug missed its endpoints in a study of 642 patients with non-active progressive MS.
Amirah Al Idrus
Mar 10, 2020 5:24pm
Roche MS candidate beats Rebif in latest PhIII as 2016 FDA decision awaits
Sep 14, 2016 6:41am
Roche’s new multiple sclerosis drug set for early FDA approval
Jun 28, 2016 5:51am
MedDay hails new progressive MS data as EMA filing beckons
Apr 21, 2016 8:46am
MedDay raises $38.5M to fund PhIII push for its multiple sclerosis drug
Apr 8, 2016 3:42am
